According to Zhitong Finance App News, Rongchang Biotech (688331.SH) released its report for the third quarter of 2026. The company achieved operating income of 6.764 billion yuan in the first three quarters, an increase of 293.28%; net profit attributable to shareholders of listed companies was 5.273 billion yuan, turning a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 4.412 billion yuan; basic earnings per share.

In the first three quarters, the year-on-year increase in the company's revenue was mainly due to increased sales of injectable tetracip and injectable viducitumab, and increased sales revenue. At the same time, the company signed an exclusive licensing agreement with AbbVie for RC148, and technical licensing revenue increased dramatically.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.